Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
RVTY Catalyst Timeline
Dated clinical, regulatory and corporate events for Revvity, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revvity, Inc.
Past FDA Catalysts and PDUFA Decisions
How RVTY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Revvity, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RVTY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gonzales AnitaOfficer (VP and CAO) | Sell | -84 7,117 held | $155.48 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RVTY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RVTY for Q3 2026. | ||||
Ownership Trends
RVTY Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RVTY ranks across every disease it competes in
RVTY News
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
Revvity, Inc. will host its 2026 Investor Day on November 13, focusing on its strategy for 'Powering Scientific Intelligence.' CEO Prahlad Singh will discuss the company's growth outlook and its differentiated portfolio in Life Sciences and Diagnostics. Revvity aims to enhance AI-enabled discovery workflows and deliver sustained shareholder value.
Read more →Revvity Announces Financial Results for the Third Quarter of 2026
Revvity, Inc. reported strong financial results for Q3 2026, with revenue reaching $729 million and adjusted EPS of $1.38. The company experienced a 7% pro forma revenue growth and raised its full-year guidance. The Life Sciences segment showed notable growth, contributing significantly to overall performance. An Investor Day is scheduled for November 13, 2026.
Read more →Revvity Board Declares Quarterly Dividend
Revvity, Inc. announced a quarterly dividend of $0.07 per share, payable on February 12, 2027. Shareholders of record by January 22, 2027, will receive this dividend. The company reported a revenue of $2.9 billion in 2025 and serves a global customer base across various sectors.
Read more →Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
Revvity, Inc. has launched its Signals LabGistics solution, aimed at enhancing scientific workflow orchestration. This AI-driven platform facilitates the connection and coordination of various processes, from initial discovery through to manufacturing. By utilizing AI to interpret natural language and standard procedures, it aims to streamline scientific operations.
Read more →Revvity to Present at Upcoming Investor Conferences
Revvity, Inc. has announced its participation in two upcoming investor conferences. The presentations will be led by Prahlad Singh, the company's CEO, who will discuss Revvity's strategic priorities. The events are scheduled for November 17 and December 2, 2026, and will include live audio webcasts.
Read more →Revvity to Host Investor Day
Revvity, Inc. has announced its 2026 Investor Day scheduled for November 13 at 9:00 a.m. ET. The event will feature presentations from senior management, focusing on the company's business initiatives, operational achievements, and financial outlook. Interested parties can register for the webcast, and a replay will be available afterward.
Read more →Revvity to Hold Earnings Call on November 3, 2026
Revvity, Inc. has announced the release of its third quarter 2026 financial results, which will occur before the market opens on November 3, 2026. The company will also host a conference call at 7:30 a.m. ET on the same day, featuring CEO Prahlad Singh and CFO Max Krakowiak to discuss the results. This event aims to provide insights to investors.
Read more →Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
Revvity, Inc. has launched the GSP® T1D 3plex kit, an automated solution for detecting autoantibodies related to type 1 diabetes (T1D). This CE-IVDR-certified kit aims to facilitate population-wide screening, allowing for early identification of children at risk before symptoms manifest. The initiative addresses a significant public health challenge associated with T1D.
Read more →Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Revvity, Inc. has announced its acquisition of Human Cell Design, a biotechnology firm based in France. This strategic move aims to enhance Revvity's Life Sciences portfolio by integrating HCD's human pancreatic beta cell models. The acquisition will support drug discovery and preclinical research for metabolic diseases such as diabetes and obesity.
Read more →Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
Revvity, Inc. has launched the SuperFlex prenatal screening system, which is CE-IVDR certified. This compact immunoassay instrument aims to provide reliable and rapid preeclampsia testing solutions for laboratories and clinics. The system is designed for lower-volume workflows, addressing the growing need for effective prenatal screening as preeclampsia rates rise globally.
Read more →Revvity Announces Financial Results for the Second Quarter of 2026
Revvity, Inc. reported its financial results for Q2 2026, showing a slight increase in GAAP earnings per share to $0.48 from $0.47 in the previous year. Revenue also rose to $730 million compared to $720 million in the same quarter last year. The company reported an operating income of $89 million.
Read more →Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs
Revvity, Inc. has announced the development of the T-SPOT™ A201, a high-throughput automated platform aimed at enhancing the accuracy and reliability of T-SPOT.TB™ testing in clinical labs. This innovation is particularly relevant for large-volume labs and addresses the growing demand for tuberculosis testing, driven by factors such as immigration screening and immunosuppressive therapy evaluations.
Read more →Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
Revvity, Inc. has launched a new program called Signals for Startups aimed at assisting emerging biotechnology companies. This initiative provides access to enterprise-grade Signals software along with guided onboarding and tailored configurations. The program is designed to help early-stage biotechs establish scalable informatics capabilities, fostering innovation from the outset.
Read more →Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Revvity, Inc. has released its 2026 Impact Report, focusing on its sustainability and governance strategies. The report details the company's initiatives aimed at translating innovation into tangible benefits while promoting responsible business practices. CEO Prahlad Sin emphasizes the importance of combining scientific innovation with sustainability.
Read more →Revvity to Hold Earnings Call on Tuesday, August 4, 2026
Revvity, Inc. (NYSE: RVTY) has announced the release of its second quarter 2026 financial results, scheduled for August 4, 2026. The company will hold a conference call at 7:30 a.m. ET on the same day to discuss these results. Key executives, including CEO Prahlad Singh and CFO Max Krakowiak, will lead the call.
Read more →Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Revvity has announced an expansion of its Signals AI ecosystem through the integration of Anthropic Claude. This move is aimed at enhancing the capabilities of their AI offerings. The integration is expected to provide users with improved insights and analytics, although specific details on functionality remain limited.
Read more →Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Revvity has introduced Signals AI, a new framework designed to accelerate scientific research and development. This innovative tool emphasizes privacy protection while enhancing the efficiency of R&D processes. The launch aims to provide researchers with advanced capabilities to drive scientific advancements.
Read more →Revvity Announces Financial Results for the First Quarter of 2026
Revvity has announced its financial results for the first quarter of 2026. The details of the financial performance and any significant changes or highlights were not provided in the article. Further insights into revenue, expenses, and future outlook are expected in subsequent communications.
Read more →